Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.

Non-GAAP Financial Measures

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company’s financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial guidance is provided below.

<table>
<thead>
<tr>
<th></th>
<th>Fiscal Year 2017</th>
<th>Fiscal Fourth-Quarter 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP diluted earnings per share</td>
<td>$0.23 - $0.25</td>
<td>$0.11 - $0.13</td>
</tr>
<tr>
<td>Acquisition – amortization of intangible assets</td>
<td>$0.48</td>
<td>$0.13</td>
</tr>
<tr>
<td>Acquisition – one time charges</td>
<td>$0.30</td>
<td>$0.02</td>
</tr>
<tr>
<td><strong>Non-GAAP diluted earnings per share</strong></td>
<td><strong>$1.01 - $1.03</strong></td>
<td><strong>$0.26 - $0.28</strong></td>
</tr>
</tbody>
</table>

For additional information on GAAP to non-GAAP reconciliation see: https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/
# Third Quarter FY2017 Financial Results

*Significantly Exceeded Expectations*

<table>
<thead>
<tr>
<th></th>
<th>3Q17 Actual Results</th>
<th>3Q16 Actual Results</th>
<th>YoY Change</th>
<th>Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$196.9</td>
<td>$190.5</td>
<td>3%</td>
<td>$188 - $190 million</td>
</tr>
<tr>
<td>GAAP EPS</td>
<td>$0.06</td>
<td>$0.47</td>
<td>(87%)</td>
<td>$0.08 - $0.10</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td>$0.27</td>
<td>$0.41</td>
<td>(34%)</td>
<td>$0.23 - $0.25</td>
</tr>
</tbody>
</table>

* Based on higher than anticipated closing costs in the quarter due to the earlier than expected closing of the Assurex acquisition
## Key Accomplishments in 3Q17

**Excellent Progress on Three Strategic Imperatives**

<table>
<thead>
<tr>
<th>Strategic Imperative</th>
<th>Accomplishment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continued Leadership in an Expanding Hereditary Cancer Market</td>
<td>• Grew hereditary cancer volume in seasonally challenging 3Q for first time in five years&lt;br&gt;• Oncology volume up sequentially for second quarter in a row</td>
</tr>
<tr>
<td>Diversify Revenue with New Products</td>
<td>• Non-hereditary cancer testing reached 68% of volume and 28% of revenue&lt;br&gt;• GeneSight volume up 44% and revenue up 41% YoY&lt;br&gt;• Completed enrollment early in major prospective clinical utility study for GeneSight&lt;br&gt;• Vectra DA volumes increased 5% sequentially returning to sequential growth&lt;br&gt;• Prolaris volume up 9% sequentially breaking 20,000 annual run rate&lt;br&gt;• Presenting Prolaris study at AUA demonstrating the ability predict metastases&lt;br&gt;• BRACAnalysis CDx successful at selecting patients in metastatic breast cancer study&lt;br&gt;• Launched EndoPredict in U.S. market; over 83 million lives now covered&lt;br&gt;• Submitted myPath Melanoma reimbursement dossier to Medicare and commercial payers</td>
</tr>
<tr>
<td>Grow Kit Products in Major International Geographies</td>
<td>• Grew revenue 41% year-over-year&lt;br&gt;• International revenue reached 5% of total revenue&lt;br&gt;• EndoPredict revenue grew 109% year-over-year&lt;br&gt;• Submitted our regulatory filing in Japan for BRACAnalysis CDx as the companion diagnostic for Lynparza in conjunction with our collaboration with AstraZeneca.</td>
</tr>
</tbody>
</table>
Fiscal Third-Quarter 2017 Revenue By Product
Achieved Highest Revenue in Last Three Years

(in millions)

<table>
<thead>
<tr>
<th>Product</th>
<th>3Q17</th>
<th>3Q16</th>
<th>YoY Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary Cancer</td>
<td>$140.8</td>
<td>$156.3</td>
<td>(10%)</td>
</tr>
<tr>
<td>GeneSight</td>
<td>$23.9</td>
<td>NA*</td>
<td>NM</td>
</tr>
<tr>
<td>Vectra DA</td>
<td>$11.2</td>
<td>$12.3</td>
<td>(9%)</td>
</tr>
<tr>
<td>Prolaris</td>
<td>$3.4</td>
<td>$5.2**</td>
<td>(35%)</td>
</tr>
<tr>
<td>EndoPredict</td>
<td>$2.3</td>
<td>$1.1</td>
<td>109%</td>
</tr>
<tr>
<td>Other</td>
<td>$3.6</td>
<td>$2.5</td>
<td>44%</td>
</tr>
<tr>
<td><strong>Total Molecular Diagnostic Revenue</strong></td>
<td><strong>$185.1</strong></td>
<td><strong>$177.4</strong></td>
<td><strong>4%</strong></td>
</tr>
<tr>
<td>Pharmaceutical &amp; Clinical Services</td>
<td>$11.7</td>
<td>$13.1</td>
<td>(11%)</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td><strong>$196.9</strong></td>
<td><strong>$190.5</strong></td>
<td><strong>3%</strong></td>
</tr>
</tbody>
</table>

* Prior to the completion of the Assurex Health acquisition
** Included Medicare retrospective payments
### Fiscal Third-Quarter Financial Results

<table>
<thead>
<tr>
<th></th>
<th>3Q17</th>
<th>3Q16</th>
<th>YoY Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Revenue</td>
<td>$196.9</td>
<td>$190.5</td>
<td>3%</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>$152.6</td>
<td>$150.3</td>
<td>2%</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>77.5%</td>
<td>78.9%</td>
<td>NM</td>
</tr>
<tr>
<td>Operating Income</td>
<td>$12.9</td>
<td>$42.6</td>
<td>(70%)</td>
</tr>
<tr>
<td>Adjusted Operating Income</td>
<td>$24.0</td>
<td>$45.8</td>
<td>(48%)</td>
</tr>
<tr>
<td>Adjusted Operating Margin</td>
<td>12.2%</td>
<td>24.0%</td>
<td>NM</td>
</tr>
<tr>
<td>Net Income</td>
<td>$4.2</td>
<td>$34.5</td>
<td>(88%)</td>
</tr>
<tr>
<td>Diluted EPS</td>
<td>$0.06</td>
<td>$0.47</td>
<td>(87%)</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td>$0.27</td>
<td>$0.41</td>
<td>(34%)</td>
</tr>
</tbody>
</table>
4Q17 and FY17 Financial Guidance
Raising Revenue Guidance; Narrowing EPS Outlook

<table>
<thead>
<tr>
<th>Metric</th>
<th>Fiscal Fourth-Quarter 2017</th>
<th>Fiscal Year 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$192 to $194 million</td>
<td>$763 to $765 million</td>
</tr>
<tr>
<td>GAAP Diluted EPS</td>
<td>$0.11 to $0.13</td>
<td>$0.23 to $0.25</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td>$0.26 to $0.28</td>
<td>$1.01 to $1.03</td>
</tr>
</tbody>
</table>

For additional information on GAAP to non-GAAP reconciliation see: [https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/](https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/)
Strongest 3Q Sequential Growth in Five Years

Sales Force Productivity and New Strategies Leading to Strong Momentum

Sequential Growth in Hereditary Cancer Quarterly Volumes

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q213-Q313</td>
<td>0.0%</td>
</tr>
<tr>
<td>Q214-Q314</td>
<td>-10.0%</td>
</tr>
<tr>
<td>Q215-Q315</td>
<td>-8.0%</td>
</tr>
<tr>
<td>Q216-Q316</td>
<td>-6.0%</td>
</tr>
<tr>
<td>Q217-Q317</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

Volume With Out-of-Network Plans Grew Sequentially
Physicians and Patients Continue To Demand Myriad’s Superior Quality

As out-of-network provider:
• Physicians continue to demand highest quality test
• Out-of-network volume grew sequentially in Q3
• Billed at list price with no discount
High Discordance in Public Databases
Myriad’s Database Provides Highest Quality Answers

Gradishar Study
n=4,250
n=1,135
27%
Conflicting interpretation between laboratories
Source: The Oncologist April 2017

PROMPT Study
n=603
n=155
26%
Conflicting interpretation between laboratories
Source: PROMPT Study presented at ASCO 2016 Annual Meeting
Substantial Diversification in Testing Volumes

> Two Thirds of Volume Attributed to Non-Hereditary Cancer Tests

**FY13**

- ≈180,000 tests
- 99% Hereditary Cancer

**FY17E**

- >600,000 tests
- ≈ 33% Hereditary Cancer

- 35% CAGR

Pie charts depict test volumes with segments for Hereditary Cancer, Prolaris, Vectra DA, GeneSight, and EndoPredict.
Reimbursement Will Drive Significant Growth

$650M Annual New Product Revenue When Fully Reimbursed

Current ASP

Target ASP

Current Revenue Run Rate at Full Reimbursement

Prolaris

$50M

$50M

$90M

$490M

$20M

$650M

Combined

$0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500
Landmark GeneSight Study Fully Enrolled
Top Line Data Expected by End of Calendar Year 2017

GeneSight showed greater than twice the improvement in HAM-D17 scores relative to trials with blockbuster depression medications

FDA Approved Medications*

*Sources: FDA summary bases of approvals
Strong New Health Economic Data For GeneSight
Mounting Evidence Supporting Substantial Cost Savings


Data presented at the Neuroscience Education Institute Annual Conference 2016
Clinical Therapeutics February 2017
Preventive Care Pilot Highly Successful
Significant Opportunity to Leverage Large Preventive Care Sales Team

TREATING PHYSICIAN FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER

- 26% 13,600 High Volume Psychiatrists
- 24% Other 35,000 Psychiatrists
- 32% Other
- 10% >200,000 Primary Care and Other
- 8% 16,000 High Volume Primary Care

Target: 30k high volume physicians account for 50% of MMD market

- Most MDD patients are seen by primary care consisting of general practice, internal medicine and OB/GYNs.
- Top 16,000 primary care physicians and OB/GYN channel order almost half of the prescriptions for MDD.
- Sales reps in pilot study generated average volumes at an annual run rate of 300 tests per year.
Clinical Guidelines Increasingly Recognize Vectra DA

ACR Diagnostic Guideline Review Will Occur This Fall

December 2016

United Rheumatology Clinical Practice Guidelines

February 2017

Creaky Joints Guidelines (Major Patient Advocacy Group)

Review in Fall 2017

American College of Rheumatology Diagnostic Guidelines
New LCD Would Expand Coverage For Prolaris

50% of Prostate Cancer Patients (>100,000/yr) Would be Covered

200,000 localized prostate cancer patients

Prolaris Insurance Coverage

- Medicare Low Risk
- Medicare (Favorable Intermediate)
- Medicare Non-Covered
- Commercial Non-Covered
- Commercial Covered
New Study Shows Ability to Predict Metastases
Adding Metastases to Clinical Report Provides Added Value to Physicians

**Mortality Risk**

- **Mortality Risk: 4.0%** 10-Year Prostate Cancer-Specific (with conservative management)

In a clinical study estimating 10-year prostate cancer-specific mortality risks for men undergoing conservative management, there were no observed prostate cancer deaths in patients with a predefined clinical risk score (CCP combined with CAPRA) corresponding to a 3.2% (95% CI 2.0, 5.2%) prostate cancer-specific mortality risk.

**Disease Specific Mortality**
This patient’s 10 year risk of prostate cancer-specific mortality is 4.0% (95% CI:2.5-5.2%) with conservative management. Mortality risks could be altered by various therapeutic interventions.

**Metastasis Risk**

- **Metastasis Risk: 1.4%** 10-Year (with definitive treatment)

This patient’s 10 year risk of metastasis is 1.4% (95% CI:0.6-2.9%) after definitive treatment.
EndoPredict Has Both Sets of Predictive Genes

Superior Ability to Predict Late-Stage Recurrence

Proliferation Genes  ER-Signaling Genes

Prediction of late-stage recurrence
0-5 years

Prediction of late-stage recurrence
5-10 years

p<0.001  p=0.298
p<0.001  p=0.204
Ramping Payer Coverage for EndoPredict
Now Covered by Plans Representing 83 Million Lives in United States

EndoPredict Insurance Coverage

- Submitted dossier to Medicare in Q317
- Favorable recommendation from BCBS tech assessment committee Evidence Street
- Coverage decisions from payers representing 83 million lives
New Indication Would Represent 60,000 Patients/Yr
3x the Size of Ovarian Cancer Market

Don't progress to metastatic disease
Diagnosed with or progress to metastatic disease

155,000
HER2- 60,000
HER2+ 40,000

255,000 cases of invasive breast cancer

Two-thirds not currently eligible for hereditary cancer testing
## Multiple PARP Clinical Studies to Report in CY17

8 Additional Pivotal Clinical Study Results Expected

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of Studies</th>
<th>First Data Expected</th>
<th>Total Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>HER2- metastatic breast cancer</td>
<td>3</td>
<td>AZN olaparib data reported - OlympiAD</td>
<td>160,000</td>
</tr>
<tr>
<td>Neoadjuvant TNBC</td>
<td>1</td>
<td>Jun. 2017</td>
<td>70,000</td>
</tr>
<tr>
<td>Other ovarian</td>
<td>3</td>
<td>AZN olaparib data reported – SOLO2</td>
<td>50,000</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>1</td>
<td>Dec. 2017</td>
<td>100,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td><strong>380,000</strong></td>
</tr>
</tbody>
</table>
Final myPath Melanoma Studies Published
*Dossier Submitted to Medicare and Private Payers*

**myPath Melanoma Diagnostic Accuracy**

<table>
<thead>
<tr>
<th>Validation</th>
<th>Patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Validation 1</td>
<td>437</td>
<td>90%</td>
</tr>
<tr>
<td>Validation 2</td>
<td>736</td>
<td>92%</td>
</tr>
<tr>
<td>Validation 3</td>
<td>182</td>
<td>95%</td>
</tr>
</tbody>
</table>

**myPath Melanoma Clinical Utility**

<table>
<thead>
<tr>
<th></th>
<th>Pre-Test</th>
<th>Post-Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indeterminate</td>
<td>38%</td>
<td>9%</td>
</tr>
<tr>
<td>Malignant</td>
<td>22%</td>
<td>11%</td>
</tr>
<tr>
<td>Benign</td>
<td>41%</td>
<td></td>
</tr>
</tbody>
</table>

n=218 patients

**Sources:**


Cockerell et al. The Influence of a Gene Expression Signature on the Diagnosis and Recommended Treatment of Melanocytic Tumors by Dermatopathologists. Medicine. 2016; 95(40):e4887
International Product Revenue Up 41%
Driven by Strong Growth and Expanding Reimbursement for EndoPredict

EndoPredict Revenue (in mil.)

- French public health care system funding began in 1H CY16 covering all patients.
- German national reimbursement (GBA) covering local testing in authorized major centers.
- Submitted to U.K. NICE and Health Canada; expect decision in 1H CY18.